Serum Proteomic Changes in Dogs with Different Stages of Chronic Heart Failure


Sarıl A., Kocatürk M., Shimada K., Uemura A., Akgün E., Levent P., ...More

ANIMALS, vol.12, no.440, pp.1-14, 2022 (Journal Indexed in SCI Expanded)

  • Publication Type: Article / Article
  • Volume: 12 Issue: 440
  • Publication Date: 2022
  • Doi Number: 10.3390/ani12040490
  • Title of Journal : ANIMALS
  • Page Numbers: pp.1-14

Abstract

Abstract: MMVD, the most common cause of CHF in dogs, is a chronic disease with variable

clinical signs, with some patients remaining asymptomatic while others develop CHF. Here, we

aimed to evaluate serum proteins by proteomic analysis in dogs at different stages of CHF due to

MMVD, and proteome behaviors after conventional treatment. A total of 32 dogs were divided

equally into four groups—stage A (healthy/controls), stage B2 (asymptomatic), stage C and stage

D (symptomatic)—according to the ACVIM consensus. Serum proteomes were evaluated using

LC/MS-based label-free differential proteome analysis. The study revealed 157 different proteins;

11 were up- and 21 down-regulated in dogs with CHF compared to controls. In stage B2 dogs,angiotensinogen (AGT) was up-regulated, but immunoglobulin iota chain-like, lipopolysaccharidebinding

protein, and carboxypeptidase (CPN) were down-regulated. In stage C dogs, complement

C3 (C3) and inter-alpha-trypsin inhibitor heavy chain were up-regulated, but hemopexin, and actincytoplasmic-

1 (ACT-1) were down-regulated. In stage D dogs, AGT was up-regulated, whereas

tetranectin, paraoxonase-1, adiponectin and ACT-1 were down-regulated. A decrease in CPN, C3

and AGT and an increase in ACT-1 were observed after treatment of dogs in stage C. This pilot study

identified that dogs at different stages of CHF show different serum protein composition which has

potential to be biomarker for diagnose and treatment monitorization.

Keywords: proteomic; mitral valve disease; heart disease; ACVIM; dogs